Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), explore potential future research directions in metastatic uveal melanoma.
Back
Key Updates in Metastatic Uveal Melanoma From ESMO 2025
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), unpack key updates in uveal melanoma, highlighting ongoing research, persisting treatment challenges, and updates from the 2025 ESMO Congress.
Key Updates in Metastatic Uveal Melanoma From ESMO 2025
Episodes
All
All
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), highlight current treatment approaches in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the use of percutaneous hepatic perfusion in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), break down data from the phase 2 CHOPIN trial evaluating percutaneous hepatic perfusion plus nivolumab and ipilimumab in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the potential clinical implications of the CHOPIN trial in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss other ways percutaneous hepatic perfusion could be integrated into metastatic uveal melanoma management.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), break down other data in metastatic uveal melanoma from the 2025 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5